WBI-4005: Novel Small Molecule Anti-Inflammatory

WBI-4005 is a novel, non-steroidal, anti-inflammatory lead candidate selected from a series of rationally designed small molecules from our drug discovery program.

The anti-inflammatory activity of the multi-targeted WBI-4005 has been demonstrated in enzymatic activity assays as well as functional cell based assays. In Vivo studies have further demonstrated WBI- 4005 to be orally bio-available and possess significant efficacy in animal disease models.

In immune cells, WBI-4005 strongly inhibits the production of multiple key inflammatory mediators and shows activity against multiple cell types including T-cells and macrophages.

WBI-4005 is under pre-clinical development for the treatment of chronic inflammatory diseases that affect millions of people worldwide.